Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | a small-molecule pocket | 0.60 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 11 Parkinson's papers of 2,570 | 0.67 |
| pathways Reactome | 10 pathways; mostly immune signalling | 0.90 |
No case: the score is under the bar. Receipt 9019
Sealed predictions
- ISG15 in dopamine neurons, braak-0.58 (p 0.102) → +0.00 (p 1.000)receipt 9027
Swarm cases
receipt 9027: ISG15 in dopamine neurons, braak
- power
- full sample -0.23 (p 0.351, n 18), 95% CI -0.63 to +0.26. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.22 (p 0.384, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.17 (p 0.504, n 18). could be the mix.
- skeptic
- leave-one-out range -0.37 to -0.11, sign flips 0; without severely affected donors -0.23 (p 0.351, n 18). fragile.
- cell type
- strongest in microglia: -0.60 (p 0.0089, n 18) vs -0.23 in dopamine neurons. proposing microglia.
- axis
- no measure beats "tracks Braak Lewy-body stage" for ISG15 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up ISG15 · microglia · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) +0.00 p 1.000 (needs p < 2.3e-4)
Receipts
loading the receipts